Compare CSW & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | TFX |
|---|---|---|
| Founded | 2014 | 1943 |
| Country | United States | United States |
| Employees | 2600 | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | N/A | 1994 |
| Metric | CSW | TFX |
|---|---|---|
| Price | $275.14 | $120.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $323.20 | $138.75 |
| AVG Volume (30 Days) | 105.7K | ★ 879.5K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | 0.38% | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $23.19 | $15.97 |
| Revenue Next Year | $19.04 | $5.15 |
| P/E Ratio | $40.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $230.45 | $100.18 |
| 52 Week High | $337.02 | $139.67 |
| Indicator | CSW | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 44.71 |
| Support Level | $254.34 | $117.09 |
| Resistance Level | $286.59 | $126.13 |
| Average True Range (ATR) | 10.52 | 4.84 |
| MACD | -2.13 | -1.99 |
| Stochastic Oscillator | 17.70 | 9.76 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.